ANTIGEN-BINDING PROTEIN FOR PROPROTEIN CONVERTASE SUBTILISIN KEKSIN TYPE 9 (PCSK9)

• Main Authors: SHAN BEI, SHEN WENYAN, JACKSON SIMON MARK, DEREK EVAN PIPER, NIGEL PELHAM CLINTON WALKER, RANDAL ROBERT KET, CAO QIONG, CHAN JOYCE CHI YEE, CHADWICK TERENCE KING, MEHLIN CHRISTOPHER, TERESA ARAZAS CARABEO
• Format: Patent
• Language: English; Japanese
• Published: 16.04.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

To provide antigen-binding proteins interacting with proprotein convertase subtilisin keksin type 9 (PCSK9).SOLUTION: Provided is an isolated neutralizing antigen-binding protein that binds to a PCSK9 protein containing a particular amino acid sequence and reduces the LDLR-lowering effect of PCSK9 on LDLR. Provided is a method for treating hypercholesterolemia and other diseases by administering a pharmaceutically effective amount of the antigen-binding protein for PCSK9. Provided is a method for detecting the amount of PCSK9 in a sample using the antigen-binding protein for PCSK9.SELECTED DRAWING: Figure 26 【課題】プロタンパク質コンベルターゼスブチリシンケクシン９型（ＰＣＳＫ９）と相互作用する抗原結合タンパク質の提供。【解決手段】特定のアミノ酸配列を含むＰＣＳＫ９タンパク質に結合し、ＬＤＬＲに対するＰＣＳＫ９のＬＤＬＲ低下効果を減少させる単離された中和抗原結合タンパク質。前記ＰＣＳＫ９に対する抗原結合タンパク質の医薬として有効な量を投与することによって高コレステロール血症及び他の疾患を治療する方法。前記ＰＣＳＫ９に対する抗原結合タンパク質を用いて、試料中のＰＣＳＫ９の量を検出する方法。【選択図】図２６